CHEK1 and cancer: MK-8776 (SCH900776), developed by Merck KGaA, is another highly selective and potent inhibitor of CHK1 (IC50 of 3 nmol/L) that is currently in phase I/II clinical trials for various cancers but has only been tested preclinically for GB therapy [286,287].